Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.R. Passos, M. Zatz.
Creatine-kinase (CK) and pyruvate-kinase (PK) activities in cord blood of normal neonates; application to Duchenne muscular dystrophy screening programmes.
Am J Med Genet, 16 (1983), pp. 367-372
[2.]
M.R. Passos, C.H. González, M. Zatz.
Creatine-kinase (CK) and pyruvate- kinase (PK) activities in normal children: implications in Duchenne muscular dystrophy carrier detection.
Am J Med Genet, 23 (1985), pp. 225-235
[3.]
Z. Argov.
Drug induced myopathies.
Current Op Neurol, 13 (2000), pp. 541-545
[4.]
F.L. Mastaglia.
Toxic myopaties.
Handbook of clinical neurology (vol. 18), pp. 595-622
[5.]
P.G. Blain, R.J.M. Lane.
Neurological disorders.
Textbook of adverse drug reactions, pp. 535-566
[6.]
J. Shepherd.
Fibrates and statins in the treatment of hyperlipidemia: an appraisal of their efficacy and safety.
Eur Heart J, 16 (1995), pp. 5-13
[7.]
S.J. Boccuzzi, T.S. Bocanegra, J.F. Walker, D.R. Shapiro, N.E. Keegan.
Long-term safety and efficacy profile of simvastatin.
Am J Cardiol, 68 (1991), pp. 1127-1131
[8.]
C. East, P.A. Alivizatos, S.M. Grundy, P.H. Jones, J.A. Farmer.
Rhabdomyolysis in patients receiveng lovastatin after cardiac transplantation [letter].
N Engl J Med, 318 (1988), pp. 47-48
[9.]
L. Pierce, D.K. Wysowski, T.P. Gross.
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
Jama, 264 (1990), pp. 71-75
[10.]
P. Reaven, J. Witzum.
Lovastatin, nicotinic acid and rhabdomyolysis [letter].
Ann Intern Med, 109 (1988), pp. 597
[11.]
J. Tobert.
Efficacy and long-term adverse effect pattern of lovastatin.
Am J Cardiol, 62 (1988), pp. 28J-33J
[12.]
C.R. Worz, M. Botorff.
The role of cytochrome P450-mediated drugdrug interactions in determining the safety of statins.
Expert Op Pharmacotherapy, 2 (2001), pp. 1119-1127
[13.]
M.H. Davidson.
Does differing metabolism by cytochrome P450 have clinical importance?.
Curr Atheroscler Reports, 2 (2000), pp. 14-19
[14.]
P.D. Thompson, J.M. Zmuda, L.J. Domalik, R.J. Zimet, J. Staggers, J.R. Guyton.
Lovastatin increases exercise-induced skeletal muscle injury.
Metabolism, 46 (1997), pp. 1206-1210
[15.]
R.C. Pasternak, S.C. Smith, C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, C. Lenfant.
ACC/AHA/NHLBI clinical advisory on the use and safety of statins.
J Am Coll Cardiol, 40 (2002), pp. 567-572
[16.]
P.H. Chong, J.D. Seeger, C. Franklin.
Clinically relevant differences between statins: implications for therapeutic selection.
Am J Med, 111 (2001), pp. 390-400
[17.]
M. Bottorff, P. Hansten.
Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors.
Arch Int Med, 160 (2000), pp. 2273-2280
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.